Scroll

glucagon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
glucagon-like peptide (GLP) analogues and agonists	2994	9007-92-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ogluo glucagon hydrochloride recombinant glucagen glucagon glucagonoid glukagon hyperglycemic-glycogenolytic factor glucagon hydrochloride glucagon HCl glucagon recombinant	A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Molecular weight: 3482.80 Formula: C153H225N43O49S CLOGP: LIPINSKI: 3 HAC: 92 HDO: 55 TPSA: 1538.74 ALOGS: -4.71 ROTB: 113

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ogluo
glucagon hydrochloride recombinant
glucagen
glucagon
glucagonoid
glukagon
hyperglycemic-glycogenolytic factor
glucagon hydrochloride
glucagon HCl
glucagon recombinant

A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)

Molecular weight: 3482.80
Formula: C153H225N43O49S
CLOGP:
LIPINSKI: 3
HAC: 92
HDO: 55
TPSA: 1538.74
ALOGS: -4.71
ROTB: 113

Drug dosage:

Dose	Unit	Route
3	mg	N
1	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
March 25, 2020	PMDA	Eli Lilly Japan K.K.
Feb. 2, 2021	EMA	XERIS PHARMACEUTICALS IRELAND LIMITED
Nov. 14, 1960	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	111.91	19.78	67	4243	74085	63410627
Vasoplegia syndrome	63.06	19.78	16	4294	1683	63483029
Hypoglycaemia	62.55	19.78	43	4267	60022	63424690
Hypotension	60.56	19.78	83	4227	272521	63212191
Toxicity to various agents	55.98	19.78	76	4234	247174	63237538
Nasal discomfort	54.72	19.78	18	4292	4742	63479970
Shock	53.94	19.78	28	4282	23435	63461277
Cardiogenic shock	48.83	19.78	24	4286	17908	63466804
Bradycardia	48.52	19.78	40	4270	73187	63411525
Necrolytic migratory erythema	47.43	19.78	6	4304	6	63484706
Pulseless electrical activity	46.67	19.78	18	4292	7503	63477209
Cardiac arrest	44.23	19.78	42	4268	92503	63392209
Hypothermia	42.50	19.78	20	4290	13561	63471151
Suicide attempt	41.87	19.78	34	4276	60884	63423828
Circulatory collapse	41.50	19.78	23	4287	21915	63462797
Rhinalgia	39.93	19.78	11	4299	1588	63483124
Hypoglycaemic seizure	35.87	19.78	8	4302	484	63484228
Overdose	34.91	19.78	41	4269	115037	63369675
Haemodynamic instability	33.35	19.78	15	4295	9175	63475537
Non-cardiogenic pulmonary oedema	32.72	19.78	8	4302	723	63483989
Infective pulmonary exacerbation of cystic fibrosis	30.75	19.78	14	4296	8803	63475909
Respiratory failure	30.41	19.78	36	4274	101822	63382890
Atrioventricular block first degree	30.03	19.78	13	4297	7260	63477452
Pulmonary oedema	28.30	19.78	26	4284	54847	63429865
Hyperglycaemia	27.98	19.78	23	4287	41844	63442868
Electrocardiogram U wave present	27.97	19.78	5	4305	96	63484616
Distributive shock	27.66	19.78	8	4302	1375	63483337
Multiple organ dysfunction syndrome	27.55	19.78	26	4284	56726	63427986
Diabetic retinal oedema	27.53	19.78	6	4304	326	63484386
Blood glucose increased	27.34	19.78	31	4279	83725	63400987
Diabetic ketoacidosis	26.96	19.78	17	4293	20488	63464224
Blood glucose decreased	26.63	19.78	17	4293	20935	63463777
Hypoxia	26.40	19.78	26	4284	59766	63424946
CSF pressure increased	26.10	19.78	5	4305	142	63484570
Multiple lentigines syndrome	25.74	19.78	5	4305	153	63484559
Lactic acidosis	25.52	19.78	21	4289	38266	63446446
Hyperdynamic left ventricle	24.92	19.78	5	4305	181	63484531
Cytotoxic oedema	24.74	19.78	5	4305	188	63484524
Cataract subcapsular	24.02	19.78	6	4304	592	63484120
Electrocardiogram P wave abnormal	23.80	19.78	5	4305	228	63484484
Mental status changes	22.86	19.78	20	4290	39579	63445133
Hyperlipidaemia	22.71	19.78	15	4295	19556	63465156
Metabolic acidosis	22.55	19.78	21	4289	45048	63439664
Colour blindness	22.20	19.78	5	4305	316	63484396
Retinal ischaemia	21.69	19.78	5	4305	351	63484361
Electrocardiogram T wave amplitude decreased	21.38	19.78	5	4305	374	63484338
Episcleritis	20.96	19.78	6	4304	994	63483718

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Soft tissue mass	134.92	24.73	30	4219	989	34951693
Multimorbidity	131.71	24.73	29	4220	913	34951769
Oesophageal perforation	124.75	24.73	29	4220	1170	34951512
Superinfection	107.95	24.73	30	4219	2489	34950193
Hypoglycaemia	101.98	24.73	70	4179	54570	34898112
Transplant failure	97.76	24.73	30	4219	3523	34949159
Lung consolidation	90.19	24.73	32	4217	5904	34946778
Hypotension	88.75	24.73	121	4128	221528	34731154
Inflammatory marker increased	87.52	24.73	30	4219	4998	34947684
Bradycardia	81.91	24.73	70	4179	75348	34877334
Oesophageal carcinoma	79.58	24.73	33	4216	9271	34943411
Immunosuppressant drug level increased	78.37	24.73	29	4220	6026	34946656
Haemoptysis	72.79	24.73	48	4201	34958	34917724
Rales	71.08	24.73	31	4218	9852	34942830
Intentional overdose	63.21	24.73	48	4201	43626	34909056
Myocardial ischaemia	62.65	24.73	34	4215	17374	34935308
Acute kidney injury	62.47	24.73	123	4126	304865	34647817
Cardiomegaly	57.92	24.73	31	4218	15407	34937275
Vasoplegia syndrome	56.74	24.73	17	4232	1839	34950843
Pulmonary vasculitis	54.50	24.73	13	4236	586	34952096
Neuritis	48.76	24.73	13	4236	921	34951761
Labelled drug-drug interaction medication error	42.44	24.73	25	4224	14914	34937768
Cardiogenic shock	42.38	24.73	31	4218	26587	34926095
Compartment syndrome	41.06	24.73	15	4234	3003	34949679
Respiratory symptom	40.36	24.73	13	4236	1784	34950898
Lower respiratory tract infection	37.63	24.73	31	4218	31606	34921076
Coma scale abnormal	36.92	24.73	15	4234	3993	34948689
Productive cough	36.74	24.73	33	4216	37780	34914902
Drug level increased	35.77	24.73	26	4223	22070	34930612
Non-cardiogenic pulmonary oedema	33.56	24.73	9	4240	652	34952030
Pulse absent	31.59	24.73	15	4234	5788	34946894
Ascites	30.93	24.73	33	4216	46538	34906144
Neurological symptom	29.66	24.73	13	4236	4172	34948510
Sleep disorder due to a general medical condition	26.91	24.73	13	4236	5208	34947474

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	169.01	19.01	114	7791	105846	79630637
Hypotension	140.48	19.01	194	7711	440123	79296360
Hypoglycaemia	140.14	19.01	100	7805	101494	79634989
Soft tissue mass	128.52	19.01	29	7876	1259	79735224
Bradycardia	126.91	19.01	106	7799	135451	79601032
Vasoplegia syndrome	121.08	19.01	34	7871	3596	79732887
Multimorbidity	120.02	19.01	28	7877	1411	79735072
Oesophageal perforation	117.58	19.01	28	7877	1543	79734940
Transplant failure	91.68	19.01	29	7876	4612	79731871
Superinfection	90.12	19.01	29	7876	4873	79731610
Cardiogenic shock	88.81	19.01	54	7851	41860	79694623
Lung consolidation	83.69	19.01	32	7873	8915	79727568
Acute kidney injury	78.29	19.01	164	7741	519240	79217243
Oesophageal carcinoma	77.05	19.01	32	7873	11052	79725431
Immunosuppressant drug level increased	69.35	19.01	28	7877	8999	79727484
Inflammatory marker increased	67.95	19.01	29	7876	10711	79725772
Haemoptysis	65.58	19.01	50	7855	55949	79680534
Cardiac arrest	64.07	19.01	82	7823	172014	79564469
Suicide attempt	59.81	19.01	56	7849	82876	79653607
Non-cardiogenic pulmonary oedema	59.03	19.01	16	7889	1483	79735000
Toxicity to various agents	58.69	19.01	129	7776	421411	79315072
Cardiomegaly	58.51	19.01	35	7870	26317	79710166
Myocardial ischaemia	56.93	19.01	34	7871	25485	79710998
Infective pulmonary exacerbation of cystic fibrosis	56.77	19.01	27	7878	12824	79723659
Pulmonary vasculitis	54.03	19.01	13	7892	748	79735735
Rales	53.54	19.01	30	7875	19971	79716512
Neuritis	43.24	19.01	13	7892	1745	79734738
Hypoglycaemic seizure	43.02	19.01	11	7894	813	79735670
Shock	42.63	19.01	35	7870	43513	79692970
Lactic acidosis	42.27	19.01	43	7862	70316	79666167
Coma scale abnormal	40.69	19.01	19	7886	8659	79727824
Pulseless electrical activity	39.97	19.01	22	7883	14138	79722345
Compartment syndrome	39.85	19.01	16	7889	5066	79731417
Respiratory depression	37.56	19.01	27	7878	27603	79708880
Respiratory symptom	33.86	19.01	14	7891	4777	79731706
Labelled drug-drug interaction medication error	33.04	19.01	25	7880	27625	79708858
Hypoxia	31.95	19.01	45	7860	103198	79633285
Hypothermia	30.40	19.01	22	7883	22724	79713759
Coma	29.87	19.01	43	7862	100606	79635877
Overdose	29.75	19.01	60	7845	184146	79552337
Productive cough	29.58	19.01	40	7865	88291	79648192
Pulse absent	29.35	19.01	16	7889	10087	79726396
Respiratory failure	28.11	19.01	58	7847	180853	79555630
Ascites	28.06	19.01	36	7869	75526	79660957
Metabolic acidosis	27.07	19.01	37	7868	82492	79653991
Distributive shock	26.53	19.01	10	7895	2677	79733806
Hypoglycaemic unconsciousness	25.90	19.01	8	7897	1175	79735308
Drug level increased	25.21	19.01	25	7880	39626	79696857
Diabetic retinal oedema	24.80	19.01	6	7899	353	79736130
Electrocardiogram U wave present	24.63	19.01	5	7900	130	79736353
Diabetic ketoacidosis	24.50	19.01	23	7882	34099	79702384
Circulatory collapse	24.41	19.01	24	7881	37644	79698839
Sepsis	24.27	19.01	70	7835	269358	79467125
Hyperdynamic left ventricle	24.11	19.01	6	7899	397	79736086
Ileus	23.44	19.01	20	7885	26191	79710292
Pleural effusion	23.07	19.01	47	7858	145215	79591268
Neurological symptom	23.03	19.01	13	7892	8770	79727713
Multiple lentigines syndrome	22.67	19.01	5	7900	195	79736288
Arthralgia	21.85	19.01	15	7890	571788	79164695
CSF pressure increased	21.39	19.01	5	7900	254	79736229
Necrolytic migratory erythema	20.50	19.01	3	7902	9	79736474
Rhinalgia	20.47	19.01	8	7897	2359	79734124
Mental status changes	20.43	19.01	29	7876	66930	79669553
Pruritus	20.14	19.01	7	7898	394641	79341842
Pulmonary alveolar haemorrhage	19.83	19.01	13	7892	11444	79725039
Rhabdomyolysis	19.58	19.01	36	7869	103095	79633388
Electrocardiogram P wave abnormal	19.53	19.01	5	7900	371	79736112
Cytotoxic oedema	19.26	19.01	5	7900	392	79736091
Haemodynamic instability	19.19	19.01	15	7890	17367	79719116

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H04AA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PANCREATIC HORMONES GLYCOGENOLYTIC HORMONES Glycogenolytic hormones
FDA PE	N0000008635	Decreased GI Motility
FDA PE	N0000008636	Decreased GI Smooth Muscle Tone
FDA PE	N0000008652	Decreased Glycolysis
FDA PE	N0000009340	Increased Gluconeogenesis
FDA PE	N0000009345	Increased Glycogenolysis
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D006728	Hormones
FDA EPC	N0000190852	Antihypoglycemic Agent
FDA EPC	N0000190853	Gastrointestinal Motility Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypoglycemic disorder	indication	237630007
Severe hypoglycaemia in patients with diabetes	indication	237633009
Gastrointestinal Radiography Adjunct	indication
Diabetes mellitus	contraindication	73211009	DOID:9351
Insulinoma	contraindication	302822000	DOID:3892
Glucagonoma	contraindication	302823005
Pheochromocytoma	contraindication	302835009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.12	acidic
pKa2	3.31	acidic
pKa3	3.79	acidic
pKa4	4.27	acidic
pKa5	9.35	acidic
pKa6	9.95	acidic
pKa7	11.89	acidic
pKa8	11.98	acidic
pKa9	12.35	acidic
pKa10	12.43	acidic
pKa11	12.5	acidic
pKa12	12.59	acidic
pKa13	12.81	acidic
pKa14	12.81	acidic
pKa15	12.95	acidic
pKa16	13.03	acidic
pKa17	13.17	acidic
pKa18	13.33	acidic
pKa19	13.38	acidic
pKa20	13.39	acidic
pKa21	13.41	acidic
pKa22	13.65	acidic
pKa23	13.7	acidic
pKa24	13.74	acidic
pKa25	13.89	acidic
pKa26	13.97	acidic
pKa27	11.27	Basic
pKa28	10.75	Basic
pKa29	10.29	Basic
pKa30	7.99	Basic
pKa31	5.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
3MG	BAQSIMI	ELI LILLY AND CO	N210134	July 24, 2019	RX	POWDER	NASAL	10213487	Feb. 16, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	DISCN	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	DISCN	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE KIT	XERIS	N212097	Aug. 20, 2021	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucagon receptor	GPCR	P47871	GLR_HUMAN	AGONIST	EC50	9	IUPHAR	CHEMBL
Glucagon-like peptide 1 receptor	GPCR	P43220	GLP1R_HUMAN	AGONIST	Ki	7	IUPHAR
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		EC50	10.70	CHEMBL
Adenylate cyclase	Enzyme		D4A3N4_RAT ADCY3_RAT ADCY2_RAT ADCY4_RAT ADCY8_RAT ADCY6_RAT ADCY5_RAT Q8CFM9_RAT		EC50	8.23	CHEMBL
Glucagon-like peptide 1 receptor	GPCR		F8V479_MACFA		EC50	10.51	CHEMBL
Glucagon-like peptide 1 receptor	GPCR		GLP1R_MOUSE		EC50	10.36	CHEMBL
Glucagon receptor	GPCR		GLR_RAT		IC50	8.82	CHEMBL

External reference:

ID	Source
D00116	KEGG_DRUG
19179-82-9	SECONDARY_CAS_RN
4017456	VANDF
C0017687	UMLSCUI
CHEBI:5391	CHEBI
CHEMBL1201618	ChEMBL_ID
CHEMBL266481	ChEMBL_ID
D005934	MESH_DESCRIPTOR_UI
DB00040	DRUGBANK_ID
1136	IUPHAR_LIGAND_ID
933	INN_ID
76LA80IG2G	UNII
16132283	PUBCHEM_CID
151823	RXNORM
14121	MMSL
4785	MMSL
585	MMSL
8000	MMSL
d00593	MMSL
002065	NDDF
007100	NDDF
10712001	SNOMEDCT_US
427742003	SNOMEDCT_US
66603002	SNOMEDCT_US
16941-32-5	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Baqsimi	HUMAN PRESCRIPTION DRUG LABEL	1	0002-6145	POWDER	3 mg	NASAL	NDA	27 sections
GlucaGen	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0053	INJECTION, POWDER, FOR SOLUTION	1 mg	SUBCUTANEOUS	NDA	24 sections
Glucagon	HUMAN PRESCRIPTION DRUG LABEL	1	63323-596	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	NDA	23 sections
Glucagon	HUMAN PRESCRIPTION DRUG LABEL	1	63323-596	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	NDA	23 sections
Glucagon	HUMAN PRESCRIPTION DRUG LABEL	1	63323-596	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	NDA	23 sections
Gvoke HypoPen 0.5 mg Auto-Injector	HUMAN PRESCRIPTION DRUG LABEL	1	72065-120	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke HypoPen 0.5 mg Auto-Injector	HUMAN PRESCRIPTION DRUG LABEL	1	72065-120	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke HypoPen 1 mg Auto-Injector	HUMAN PRESCRIPTION DRUG LABEL	1	72065-121	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke HypoPen 1 mg Auto-Injector	HUMAN PRESCRIPTION DRUG LABEL	1	72065-121	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke PFS0.5 mg Pre-filled Syringe	HUMAN PRESCRIPTION DRUG LABEL	1	72065-130	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke PFS0.5 mg Pre-filled Syringe	HUMAN PRESCRIPTION DRUG LABEL	1	72065-130	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke PFS1 mg Pre-filled Syringe	HUMAN PRESCRIPTION DRUG LABEL	1	72065-131	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke PFS1 mg Pre-filled Syringe	HUMAN PRESCRIPTION DRUG LABEL	1	72065-131	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke Kit	HUMAN PRESCRIPTION DRUG LABEL	1	72065-140	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke Kit	HUMAN PRESCRIPTION DRUG LABEL	1	72065-140	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke KitVial	HUMAN PRESCRIPTION DRUG LABEL	1	72065-141	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections
Gvoke KitVial	HUMAN PRESCRIPTION DRUG LABEL	1	72065-141	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	20 sections